SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
about
Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.PharmGKB summary: gemcitabine pathwayEnhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.Genome-wide association analysis on normal hearing function identifies PCDH20 and SLC28A3 as candidates for hearing function and loss.Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioningA genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer.
P2860
SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
SLC28A3 genotype and gemcitabi ...... n patients with solid tumours.
@en
SLC28A3 genotype and gemcitabi ...... n patients with solid tumours.
@nl
type
label
SLC28A3 genotype and gemcitabi ...... n patients with solid tumours.
@en
SLC28A3 genotype and gemcitabi ...... n patients with solid tumours.
@nl
prefLabel
SLC28A3 genotype and gemcitabi ...... n patients with solid tumours.
@en
SLC28A3 genotype and gemcitabi ...... n patients with solid tumours.
@nl
P2093
P2860
P356
P1476
SLC28A3 genotype and gemcitabi ...... n patients with solid tumours.
@en
P2093
B W Williams
E W Greeno
K M Skubitz
M N Kirstein
R A Kratzke
P2860
P2888
P304
P356
10.1038/BJC.2013.738
P407
P577
2013-12-03T00:00:00Z